| 1 |
Barbara G, Cremon C, Bellini M, Corsetti M, Di Nardo G, Falangone F, Fuccio L, Galeazzi F, Iovino P, Sarnelli G, Savarino EV, Stanghellini V, Staiano A, Stasi C, Tosetti C, Turco R, Ubaldi E, Zagari RM, Zenzeri L, Marasco G. Italian guidelines for the management of irritable bowel syndrome: Joint Consensus from the Italian Societies of: Gastroenterology and Endoscopy (SIGE), Neurogastroenterology and Motility (SINGEM), Hospital Gastroenterologists and Endoscopists (AIGO), Digestive Endoscopy (SIED), General Medicine (SIMG), Gastroenterology, Hepatology and Pediatric Nutrition (SIGENP) and Pediatrics (SIP). Dig Liver Dis 2023;55:187-207. [PMID: 36517261 DOI: 10.1016/j.dld.2022.11.015] [Reference Citation Analysis]
|
| 2 |
Ohbayashi H, Sato Y, Kiuchi M, Nagazumi A, Kanzo T, Kimura T. Analysis of the impact on efficacy of lubiprostone dose reduction to manage adverse events in the treatment of chronic constipation in Japan. Expert Rev Gastroenterol Hepatol 2022;16:809-17. [PMID: 35993999 DOI: 10.1080/17474124.2022.2114455] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
Deutsch D, Bouchoucha M, Uzan J, Raynaud JJ, Sabate JM, Benamouzig R. Abdominal Pain Severity Is Mainly Associated with Bloating Severity in Patients with Functional Bowel Disorders and Functional Abdominal Pain. Dig Dis Sci 2022;67:3026-35. [PMID: 34324087 DOI: 10.1007/s10620-021-07175-z] [Reference Citation Analysis]
|
| 4 |
Kindt S, Louis H, De Schepper H, Arts J, Caenepeel P, De Looze D, Gerkens A, Holvoet T, Latour P, Mahler T, Mokaddem F, Nullens S, Piessevaux H, Poortmans P, Rasschaert G, Surmont M, Vafa H, Van Malderen K, Vanuytsel T, Wuestenberghs F, Tack J. Belgian consensus on irritable bowel syndrome. AGEB 2022;85:360-382. [DOI: 10.51821/85.2.10100] [Reference Citation Analysis]
|
| 5 |
Barberio B, Savarino EV, Black CJ, Ford AC. Placebo Response Rates in Trials of Licensed Drugs for Irritable Bowel Syndrome With Constipation or Diarrhea: Meta-analysis. Clin Gastroenterol Hepatol 2022;20:e923-44. [PMID: 34425274 DOI: 10.1016/j.cgh.2021.08.025] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 6 |
Cheah JX, Khanna D, Mcmahan ZH. Management of scleroderma gastrointestinal disease: Lights and shadows. Journal of Scleroderma and Related Disorders. [DOI: 10.1177/23971983221086343] [Reference Citation Analysis]
|
| 7 |
Rangan V, Singh P, Ballou S, Hassan R, Yu V, Katon J, Nee J, Iturrino J, Lembo A. Improvement in constipation and diarrhea is associated with improved abdominal pain in patients with functional bowel disorders. Neurogastroenterol Motil 2022;34:e14253. [PMID: 34520617 DOI: 10.1111/nmo.14253] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 8 |
Fortea M, Albert-Bayo M, Abril-Gil M, Ganda Mall JP, Serra-Ruiz X, Henao-Paez A, Expósito E, González-Castro AM, Guagnozzi D, Lobo B, Alonso-Cotoner C, Santos J. Present and Future Therapeutic Approaches to Barrier Dysfunction. Front Nutr 2021;8:718093. [PMID: 34778332 DOI: 10.3389/fnut.2021.718093] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 9 |
Liu JJ, Brenner DM. Focus on Pharmacotherapy for Irritable Bowel Syndrome with Constipation. Gastroenterol Clin North Am 2021;50:639-53. [PMID: 34304792 DOI: 10.1016/j.gtc.2021.04.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 10 |
Zheng H, Jin S, Shen YL, Peng WY, Ye K, Tang TC, Zhao J, Chen M, Li ZG. Chinese Herbal Medicine for Irritable Bowel Syndrome: A Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials. Front Pharmacol 2021;12:694741. [PMID: 34385918 DOI: 10.3389/fphar.2021.694741] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 11 |
Nelson AD, Black CJ, Houghton LA, Lugo-Fagundo NS, Lacy BE, Ford AC. Systematic review and network meta-analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2021;54:98-108. [PMID: 34114657 DOI: 10.1111/apt.16437] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 12 |
Fikree A, Byrne P. Management of functional gastrointestinal disorders. Clin Med (Lond) 2021;21:44-52. [PMID: 33479067 DOI: 10.7861/clinmed.2020-0980] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 13 |
Ohbayashi H, Sato Y, Kiuchi M, Asano T, Nagazumi A, Kimura T. Open-label study to evaluate the treatment continuation rate after a dose reduction of lubiprostone due to onset of adverse events. Expert Rev Gastroenterol Hepatol 2021;15:333-42. [PMID: 33206011 DOI: 10.1080/17474124.2021.1833714] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 14 |
Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, Moshiree B. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol 2021;116:17-44. [PMID: 33315591 DOI: 10.14309/ajg.0000000000001036] [Cited by in Crossref: 172] [Cited by in F6Publishing: 152] [Article Influence: 86.0] [Reference Citation Analysis]
|
| 15 |
Passos MDCF, Takemoto MLS, Corradino GC, Guedes LS. Systematic review with meta-analysis: lubiprostone efficacy on the treatment of patients with constipation. Arq Gastroenterol 2020;57:498-506. [DOI: 10.1590/s0004-2803.202000000-83] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 16 |
Stemboroski L, Schey R. Treating Chronic Abdominal Pain in Patients with Chronic Abdominal Pain and/or Irritable Bowel Syndrome. Gastroenterol Clin North Am 2020;49:607-21. [PMID: 32718573 DOI: 10.1016/j.gtc.2020.05.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 17 |
Mousavi T, Nikfar S, Abdollahi M. An update on efficacy and safety considerations for the latest drugs used to treat irritable bowel syndrome. Expert Opin Drug Metab Toxicol 2020;16:583-604. [PMID: 32380874 DOI: 10.1080/17425255.2020.1767067] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 18 |
Li B, Liang L, Deng H, Guo J, Shu H, Zhang L. Efficacy and Safety of Probiotics in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis.Front Pharmacol. 2020;11:332. [PMID: 32317962 DOI: 10.3389/fphar.2020.00332] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 19 |
Mari A, Mahamid M, Amara H, Baker FA, Yaccob A. Chronic Constipation in the Elderly Patient: Updates in Evaluation and Management. Korean J Fam Med 2020;41:139-45. [PMID: 32062960 DOI: 10.4082/kjfm.18.0182] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 20 |
Ruszkowski J, Heleniak Z, Król E, Tarasewicz A, Gałgowska J, Witkowski JM, Dębska-Ślizień A. Constipation and the Quality of Life in Conservatively Treated Chronic Kidney Disease Patients: A Cross-sectional Study. Int J Med Sci 2020;17:2954-63. [PMID: 33173416 DOI: 10.7150/ijms.49648] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 21 |
Munjal A, Dedania B, Cash B. Update on Pharmacotherapy for Irritable Bowel Syndrome. Curr Gastroenterol Rep 2019;21. [DOI: 10.1007/s11894-019-0692-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 22 |
Saito YA, Almazar AE, Tilkes KE, Choung RS, Van Norstrand MD, Schleck CD, Zinsmeister AR, Talley NJ. Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome. Aliment Pharmacol Ther 2019;49:389-97. [PMID: 30663077 DOI: 10.1111/apt.15077] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 23 |
Zong Y, Zhu S, Zhang S, Zheng G, Wiley JW, Hong S. Chronic stress and intestinal permeability: Lubiprostone regulates glucocorticoid receptor-mediated changes in colon epithelial tight junction proteins, barrier function, and visceral pain in the rodent and human. Neurogastroenterol Motil 2019;31:e13477. [PMID: 30284340 DOI: 10.1111/nmo.13477] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 24 |
Pietrzak A, Skrzydło-Radomańska B, Mulak A, Lipiński M, Małecka-Panas E, Reguła J, Rydzewska G. Guidelines on the management of irritable bowel syndrome: In memory of Professor Witold Bartnik. Prz Gastroenterol 2018;13:259-88. [PMID: 30581501 DOI: 10.5114/pg.2018.78343] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 25 |
Black CJ, Burr NE, Quigley EMM, Moayyedi P, Houghton LA, Ford AC. Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis. Gastroenterology 2018;155:1753-63. [PMID: 30144426 DOI: 10.1053/j.gastro.2018.08.021] [Cited by in Crossref: 100] [Cited by in F6Publishing: 100] [Article Influence: 20.0] [Reference Citation Analysis]
|
| 26 |
Pannemans J, Tack J. How Effective Are Secretagogues for Irritable Bowel Syndrome With Constipation. Gastroenterology 2018;155:1677-9. [PMID: 30419211 DOI: 10.1053/j.gastro.2018.11.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 27 |
Bharucha AE, Sharma M. Painful and Painless Constipation: All Roads Lead to (A Change in) Rome. Dig Dis Sci 2018;63:1671-4. [PMID: 29564675 DOI: 10.1007/s10620-018-5027-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 28 |
Lubiprostone. Reactions Weekly 2017;1635:193-193. [DOI: 10.1007/s40278-017-25442-2] [Reference Citation Analysis]
|
